Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 3/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29541686 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| Hydrochloric Acid SCHEMBL29361019 | 0.99 | TGFBR1 (0.98) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| Hydrochloric Acid SCHEMBL14778775 | 0.99 | TGFBR1 (0.98) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| SCHEMBL29358831 | 0.99 | TGFBR1 (1.00) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| SCHEMBL373422 | 0.99 | TGFBR1 (1.00) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| SCHEMBL29378125 | 0.99 | TGFBR1 (1.00) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| Water SCHEMBL21459280 | 0.98 | TGFBR1 (0.98) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| Hypochlorous Acid SCHEMBL26968133 | 0.95 | TGFBR1 (0.92) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| SCHEMBL4969183 | 0.90 | TGFBR1 (0.84) | TGFBR1MAPK14ACVR1BRIPK2TDP1 | |
| Hydrochloric Acid SCHEMBL29868042 | 0.85 | TGFBR1 (0.74) | TGFBR1MAPK14ACVR1BRIPK2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273655-A1 | PRODUCING ASTROCYTES USING SMALL MOLECULES | CITY OF HOPE (US) | 2022-09-01 | — | — | US | claimed |
| EP-2951290-B1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) | US HEALTH (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| US-20090181420-A1 | Inhibiting Smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION | 2009-07-16 | — | — | US | claimed |
| US-7524640-B2 | Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260035667-A1 | RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2009117439-A2 | COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090181420-A1 | Inhibiting Smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION | 2009-07-16 | — | — | US | disclosed |
| EP-2058388-A1 | Non-conventional NKT cells for use in cancer therapy | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-05-13 | — | — | EP | disclosed |
| US-7524640-B2 | Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| WO-2009043931-A1 | NON-CONVENTIONAL NKT CELLS FOR USE IN CANCER THERAPY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009021293-A1 | AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008140545-A2 | INHIBITING SMAD SIGNALING PROMOTES NEURON REGENERATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080031911-A1 | Inhibiting smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION, DUKE UNIVERSITY | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | GSK3B, GSK3A, WNT3A | MAPK14 133/4885PRKD3 35/4885TGFBR1 214/4885 |
| US-20260035667-A1 | RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLS | IAPP, PAX8, PROX1 | MAPK14 3291/4885PRKD3 1824/4885TGFBR1 3145/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885PRKD3 259/4885TGFBR1 443/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | MAPK14 149/4885PRKD3 115/4885TGFBR1 14/4885 |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, PNLIP, PPARD | MAPK14 1957/4885PRKD3 184/4885TGFBR1 977/4885 |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | KIT, FLT1, HGF | MAPK14 45/4885PRKD3 473/4885TGFBR1 11/4885 |
| US-20220273655-A1 | PRODUCING ASTROCYTES USING SMALL MOLECULES | CHAT, GMFG, DCX | MAPK14 2977/4885PRKD3 1516/4885TGFBR1 3711/4885 |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD14, HGF | MAPK14 1087/4885PRKD3 1225/4885TGFBR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.